vasicinone has been researched along with Alzheimer Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Emami, S; Haghighijoo, Z; Moosavi, F; Zamani, L | 1 |
| Du, H; Jiang, X; Liu, S; Ma, F; Ma, M; Xu, H | 1 |
| Ayyadevara, S; Balasubramaniam, M; Bowroju, SK; Crooks, PA; Lakkaniga, NR; Penthala, NR; Shmookler Reis, RJ | 1 |
1 review(s) available for vasicinone and Alzheimer Disease
| Article | Year |
|---|---|
Therapeutic potential of quinazoline derivatives for Alzheimer's disease: A comprehensive review.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Enzyme Inhibitors; Humans; Monoamine Oxidase; Neuroprotective Agents; Phosphoric Diester Hydrolases; Quinazolines; tau Proteins | 2022 |
2 other study(ies) available for vasicinone and Alzheimer Disease
| Article | Year |
|---|---|
Novel deoxyvasicinone and tetrahydro-beta-carboline hybrids as inhibitors of acetylcholinesterase and amyloid beta aggregation.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Carbolines; Cell Line; Cholinesterase Inhibitors; Humans; Molecular Docking Simulation; Peptide Fragments; Protein Aggregates; Protein Aggregation, Pathological | 2020 |
Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer's disease.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Animals; Benzylamines; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Electrophorus; Horses; Humans; Molecular Structure; Neuroprotective Agents; Peptide Fragments; Protein Aggregates; Structure-Activity Relationship | 2021 |